Gonorrhoea Antimicrobial Surveillance Programme (GASP)
A majority of laboratories in Asia conduct AMR testing only for ceftriaxone resistance, with only a few countries and areas monitoring for oral cephalosporins, such as cefixime (Hong Kong [China], Japan, the Philippines, and Thailand), ceftibuten (Hong Kong [China]) and cefuroxime (Sri Lanka). There have also been reports of reduced susceptibility to third-generation cephalosporins. Decreased cephalosporin susceptibility was associated with treatment failures with oral cephalosporins in Hong Kong (China). Treatment failure was also observed in Japan. About 30%–40% of strains in China have demonstrated decreased susceptible to ceftriaxone. Sri Lanka has reported treatment failure with extended dose of cefuroxime since March 2009.
Spectinomycin resistance is monitored in only a few countries and areas in Asia. These include Bhutan, China, Hong Kong (China), Japan, the Philippines, Sri Lanka and Thailand. Sporadic resistant cases are reported, but overall resistance remains low. It must also be noted that spectinomcyin is not readily available in the majority of countries in Asia, including India.
Tetracycline resistance has been reported in Bhutan, China, Hong Kong (China), the Philippines, Sri Lanka and India. Sri Lanka (10.5%) reported a lower proportion of tetracycline resistance.
Japan is one of a few countries monitoring azithromycin resistance. Current data show that the gonococcus is still susceptible to azithromycin.